Pandemic and All-Hazards Preparedness Act

Last updated
Pandemic and All Hazards Preparedness Act
Great Seal of the United States (obverse).svg
Long titleAn act to amend the Public Health Service Act with respect to Public Health Security and all-hazards preparedness and response, and for other purposes.
Enacted bythe 109th United States Congress
Citations
Public law 109-417
Legislative history

On December 19, 2006, the Pandemic and All-Hazards Preparedness Act (PAHPA), Public Law No. 109-417, was signed into law by President George W. Bush. First introduced in the House by Rep. Mike Rogers (R-MI) and Rep. Anna Eshoo (D-CA), PAHPA had broad implications for the United States Department of Health and Human Services's (HHS) preparedness and response activities. Among other things, the act amended the Public Health Service Act to establish within the department a new Assistant Secretary for Preparedness and Response (ASPR); provided new authorities for a number of programs, including the advanced development and acquisitions of medical countermeasures; and called for the establishment of a quadrennial National Health Security Strategy.

Contents

The purpose of the Pandemic and All-Hazards Preparedness Act is "to improve the Nation's public health and medical preparedness and response capabilities for emergencies, whether deliberate, accidental, or natural." [1]

The law was most recently reauthorized by Congress in 2013. [2] After it lapsed, an amended version, the Pandemic All-Hazards Preparedness and Advancing Innovation Act, was signed into law in June 2019. [3]

Major program areas

Provisions

Title I: National Preparedness and Response, Leadership, Organization, and Planning

Title II: Public Health Security Preparedness

Title III: All-Hazards Medical Surge Capacity

Funding

In January 2018, the Senate Health, Education, Labor and Pensions (HELP) Committee held two separate hearings on the reauthorization of the PAHPA law. The conclusion from many witnesses who testified before the hearings is that "decreased and episodic funding from the United States government has stakeholders questioning the true commitment federal lawmakers have for sustaining the nation's preparedness and response capabilities during a catastrophic event linked to infectious diseases, natural disasters or chemical, biological, radiological or nuclear (CBRN) agents." [2]

Many provisions in PAHPA are set to expire in September 2018 unless Congress reauthorizes them. [2]

PAHPA expired October 1, 2018. A revised authorization, in the form of the "Pandemic and All-Hazards Preparedness and Advancing Innovation Act", was signed into law June 28, 2019. [5]

One of the two January 2018 committee hearings focused on the private sector's relationship with providing preparedness and response capabilities. Private sector witnesses expressed concerns about the decreased or lack of federal funding for preparedness and response, saying that it's gotten to the point where the U.S. government's reputation is at stake with companies and public health and medical professionals. [2]

"Unfortunately, over the last several years, the private sector has become more skeptical of the government's commitment to biodefense," testified Brent MacGregor of Seqirus, a global influenza vaccine developer and manufacturer. [2]

PAHPA reauthorization

Like many laws that authorize activities for federal agencies, PAHPA must be reauthorized by its expiration date in order for the law to continue taking effect. As of January 2018, most of the provisions in PAHPA are set to expire in September 2018. The Senate HELP Committee started the process of reauthorizing the law with a set of hearings beginning on January 17, 2018. [6]

U.S. Senator Richard Burr (R-NC) sponsored both Senate versions of PAHPA authorization and reauthorization. The original bill, S. 3678, which created PAHPA, became law in 2006. In 2013, Burr sponsored the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) of 2013, S. 242, which became law that same year. [6]

On May 15, 2018, Burr introduced the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (bill number S. 2852). Original cosponsors of the bill were U.S. Senators Bob Casey (D-PA), Lamar Alexander (R-TN), and Patty Murray (D-WA). [7]

The Alliance for Biosecurity and U.S. Chamber of Commerce wrote a joint letter to all U.S. House members urging their passage of the House version, H.R. 6378 (the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018). [8] Congresswoman Susan Brooks (R-IN) introduced companion legislation in the House of Representatives (H.R. 6378). The bill increases funding to the U.S. Department of Health and Human Services to develop responses to pandemics and biological threats. Congresswoman Anna Eshoo (D-CA), who coauthored the bill with Brooks, called it "critical to our national security." [9]

On June 15, 2018, the U.S. House Energy and Commerce Subcommittee on Oversight and Investigations held a hearing focused on discussing biopreparedness oversight issues and stressing the need to reauthorize PAHPA. One of the witnesses, Rick Bright, director of the Biomedical Advanced Research and Development Authority (BARDA), proposed that "cutting-edge testing tools" developed by private companies should go directly to doctors' offices for "rapid, regional response to outbreaks, rather than funneling samples primarily to the CDC for testing." [10]

The chairman of the HELP Committee, Senator Lamar Alexander (R-TN), said, "I look forward to a timely, bipartisan reauthorization of this crucial legislation to ensure we are prepared to respond to natural disasters like hurricanes, and protect Americans against bioterror attacks and infectious disease outbreaks, like the Zika virus or a pandemic influenza." [6]

The purpose of reauthorizing PAHPA is to protect public health from threats coming from exposure to infectious diseases, natural disasters or chemical, biological, radiological or nuclear (CBRN) agents. [6]

During the committee hearing, Burr said that the U.S. is not fully prepared and that gaps have left the U.S. vulnerable to both terrorists and natural threats. He said that developing countermeasures "should be top of mind." [6]

See also

Related Research Articles

Biodefense refers to measures to restore biosecurity to a group of organisms who are, or may be, subject to biological threats or infectious diseases. Biodefense is frequently discussed in the context of biowar or bioterrorism, and is generally considered a military or emergency response term.

<span class="mw-page-title-main">United States Department of Health and Human Services</span> Department of the US federal government

The United States Department of Health and Human Services (HHS) is a cabinet-level executive branch department of the U.S. federal government created to protect the health of the U.S. people and providing essential human services. Its motto is "Improving the health, safety, and well-being of America". Before the separate federal Department of Education was created in 1979, it was called the Department of Health, Education, and Welfare (HEW).

The Strategic National Stockpile (SNS), originally called the National Pharmaceutical Stockpile (NPS), is the United States' national repository of antibiotics, vaccines, chemical antidotes, antitoxins, and other critical medical supplies. Its website states:

"The Strategic National Stockpile's role is to supplement state and local supplies during public health emergencies. Many states have products stockpiled, as well. The supplies, medicines, and devices for life-saving care contained in the stockpile can be used as a short-term stopgap buffer when the immediate supply of adequate amounts of these materials may not be immediately available."

Stewart Simonson is the Assistant Director-General of the World Health Organization responsible for the WHO Office at the United Nations and the WHO-US Liaison Office. He also serves as the Director-General's Special Representative for UN Reform. Prior to his assignment in New York, Simonson was the Assistant Director-General for the General Management Group at WHO headquarters in Geneva, Switzerland.

The Biodefense and Pandemic Vaccine and Drug Development Act of 2005, nicknamed "Bioshield Two" and sponsored by Senator Richard Burr, aims to shorten the pharmaceutical development process for new vaccines and drugs in case of a pandemic, and to protect vaccine makers and the pharmaceutical industry from legal liability for vaccine injuries. The proposed bill would create a new federal agency, the Biomedical Advanced Research and Development Agency (BARDA), that would act "as the single point of authority" to promote advanced research and development of drugs and vaccines in response to bioterrorism and natural disease outbreaks, while shielding the agency from public Freedom of Information Act (FOIA) requests. BARDA would be exempt from long-standing open records and meetings laws that apply to most government departments.

<span class="mw-page-title-main">National Disaster Medical System</span>

The National Disaster Medical System (NDMS) is a federally coordinated disaster medical system and partnership of the United States Departments of Health and Human Services (HHS), Homeland Security (DHS), Defense (DOD), and Veterans Affairs (VA). The purpose of the NDMS is to support State, local, Tribal and Territorial authorities following disasters and emergencies by supplementing health and medical systems and response capabilities. NDMS would also support the military and the Department of Veterans Affairs health care systems in caring for combat casualties, should requirements exceed their capacity. The NDMS was established in 1984.

<span class="mw-page-title-main">Public Readiness and Emergency Preparedness Act</span> US law

The Public Readiness and Emergency Preparedness Act (PREPA), passed by the United States Congress and signed into law by President of the United States George W. Bush in December 2005, is a controversial tort liability shield intended to protect vaccine manufacturers from financial risk in the event of a declared public health emergency. The part of PREPA that actually affords such protection is now codified at 42 U.S.C. § 247d-6d. The act specifically affords to drug makers immunity from actions related to the manufacture, testing, development, distribution, administration and use of medical countermeasures against chemical, biological, radiological and nuclear agents of terrorism, epidemics, and pandemics. PREPA strengthens and consolidates the oversight of litigation against pharmaceutical companies under the purview of the secretary of Health and Human Services (HHS). PREPA provides $3.8 billion for pandemic influenza preparedness to protect public health in the case of a pandemic disease outbreak.

<span class="mw-page-title-main">Project Bioshield Act</span> US law

The Project Bioshield Act was an act passed by the United States Congress in 2004 calling for $5 billion for purchasing vaccines that would be used in the event of a bioterrorist attack. This was a ten-year program to acquire medical countermeasures to biological, chemical, radiological, and nuclear agents for civilian use. A key element of the Act was to allow stockpiling and distribution of vaccines which had not been tested for safety or efficacy in humans, due to ethical concerns. Efficacy of such agents cannot be directly tested in humans without also exposing humans to the chemical, biological, or radioactive threat being treated, so testing follows the FDA Animal Rule for pivotal animal efficacy.

The United States National Response Framework (NRF) is part of the National Strategy for Homeland Security that presents the guiding principles enabling all levels of domestic response partners to prepare for and provide a unified national response to disasters and emergencies. Building on the existing National Incident Management System (NIMS) as well as Incident Command System (ICS) standardization, the NRF's coordinating structures are always in effect for implementation at any level and at any time for local, state, and national emergency or disaster response.

The Emergency System for Advance Registration of Volunteer Health Professionals (ESAR-VHP) is a United States federal program to establish and implement guidelines and standards for the registration, credentialing, and deployment of medical professionals in the event of a large scale national emergency. The program is administered under the Assistant Secretary for Preparedness & Response (ASPR) within the Office of Public Health Emergency Preparedness of the United States Department of Health and Human Services. The ESAR-VHP standards are mandated to American states and territories, enabling an enhanced national interstate and intrastate system for using and sharing medical professionals.

<span class="mw-page-title-main">Biomedical Advanced Research and Development Authority</span> Government organization in Washington D.C., United States

The Biomedical Advanced Research and Development Authority (BARDA)' is a U.S. Department of Health and Human Services (HHS) office responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging diseases. BARDA was established in 2006 through the Pandemic and All-Hazards Preparedness Act (PAHPA) and reports to the Office of the Assistant Secretary for Preparedness and Response (ASPR). The office manages Project BioShield, which funds the research, development and stockpiling of vaccines and treatments that the government could use during public health emergencies such as chemical, biological, radiological or nuclear (CBRN) attacks.

<span class="mw-page-title-main">Administration for Strategic Preparedness and Response</span> US government agency

The Administration for Strategic Preparedness and Response (ASPR) is an operating agency of the U.S. Public Health Service within the Department of Health and Human Services that focuses preventing, preparing for, and responding to the adverse health effects of public health emergencies and disasters. Its functions include preparedness planning and response; building federal emergency medical operational capabilities; countermeasures research, advance development, and procurement; and grants to strengthen the capabilities of hospitals and health care systems in public health emergencies and medical disasters. The office provides federal support, including medical professionals through ASPR’s National Disaster Medical System, to augment state and local capabilities during an emergency or disaster.

PublicHealthEmergency.gov is a web portal created by the U.S. Department of Health and Human Services to serve as a single point of entry for access to public health risk, and situational awareness information when the President or the Secretary of Health and Human Services exercise their public health emergency legal authority. This site acts as a portal for residents in the U.S. and worldwide to obtain information from all U.S. federal agencies involved in a public health emergency, a medical disaster or the public health aspects of a natural or man-made disaster.

<span class="mw-page-title-main">Public health emergency (United States)</span>

In the United States, a public health emergency declaration releases resources meant to handle an actual or potential public health crisis. Recent examples include:

An Emergency Use Authorization (EUA) in the United States is an authorization granted to the Food and Drug Administration (FDA) under sections of the Federal Food, Drug, and Cosmetic Act as added to and amended by various Acts of Congress, including by the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), as codified by 21 U.S.C. § 360bbb-3, to allow the use of a drug prior to approval. It does not constitute approval of the drug in the full statutory meaning of the term, but instead authorizes the FDA to facilitate availability of an unapproved product, or an unapproved use of an approved product, during a declared state of emergency from one of several agencies or of a "material threat" by the Secretary of Homeland Security.

Biosecurity in the United States is governed by the Bureau of Western Hemisphere Affairs, which is part of the US Department of State. It obtains guidance and advice on specific matters relating to biosecurity from various other government agencies.

<span class="mw-page-title-main">Pandemic and All-Hazards Preparedness Reauthorization Act of 2013</span>

The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 is a law enacted by the 113th United States Congress. The Act amends the Public Health Service Act in order to extend, fund, and improve several programs designed to prepare the United States and health professionals in the event of a pandemic, epidemic, or biological, chemical, radiological, or nuclear accident or attack. The Act clarifies the authority of different American officials, makes it easier to temporarily reassign personnel to respond to emergency situations, and alters the process for testing and producing medical countermeasures. The Act is focused on improving preparedness for any public health emergency.

The Bipartisan Commission on Biodefense, formerly known as the Blue Ribbon Study Panel on Biodefense, is an organization of former high-ranking government officials that analyzes US capabilities and capacity to defend against biological threats. According to the Commission's mission statement, the organization was formed to "provide for a comprehensive assessment of the state of U.S. biodefense efforts, and to issue recommendations that will foster change."

<span class="mw-page-title-main">Strengthening Public Health Emergency Response Act of 2015</span>

The Strengthening Public Health Emergency Response Act of 2015, H.R. 3299, is a bill introduced in the U.S. House of Representatives that would streamline government decisions and provide incentives for vaccines and treatment of dangerous pathogens and diseases. The bill was introduced by Representatives Susan Brooks (R-IN) and Anna Eshoo (D-CA).

<span class="mw-page-title-main">Alliance for Biosecurity</span>

The Alliance for Biosecurity is a consortium of companies that develop products to respond to national security threats, including bioterrorism pathogens and emerging infectious diseases. It is headquartered in Washington DC.

References

  1. "Pandemic and All Hazards Preparedness Act" (PDF). U.S. Government Publishing Office. December 19, 2006.
  2. 1 2 3 4 5 Riley, Kim (2018-01-24). "PAHPA hearing witnesses question U.S. government's preparedness, response commitment". Homeland Preparedness News. Retrieved February 27, 2018.
  3. "Pandemic All-Hazards Preparedness and Advancing Innovation Act Signed Into Law NEHA News Release".
  4. "S.3678 - Pandemic and All-Hazards Preparedness Act". Congress.gov. December 19, 2006.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  5. "S.1379 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019". congress.gov. 24 June 2019.
  6. 1 2 3 4 5 Riley, Kim (January 18, 2018). "Senate health committee begins reapproval process for nation's hazards preparedness law - Homeland Preparedness News". Homeland Preparedness News. Retrieved 2018-02-27.
  7. Riley, Kim (May 17, 2018). "Sen. Burr introduces bipartisan bill to update U.S. bioterror, pandemics law". Homeland Preparedness News. Retrieved June 26, 2018.
  8. Kingston, Jack; Bradley, Neil L. (July 27, 2018). "Letter to the Members of the U.S. House of Representatives" (PDF). Alliance for Biosecurity and U.S. Chamber of Commerce.
  9. Riley, Kim (2018-09-26). "House approves Rep. Brooks' pandemic, all-hazards reauthorization bill". Homeland Preparedness News. Retrieved October 25, 2018.
  10. Adrien, Claudia (June 18, 2018). "National agencies seek biopreparedness funding, discuss new technologies to stem emerging threats". Homeland Preparedness News. Retrieved June 26, 2018.